MY178870A - Attenuated recombinant alphaviruses incapable of replicating in mosquitoes and uses thereof - Google Patents
Attenuated recombinant alphaviruses incapable of replicating in mosquitoes and uses thereofInfo
- Publication number
- MY178870A MY178870A MYPI2010003463A MYPI2010003463A MY178870A MY 178870 A MY178870 A MY 178870A MY PI2010003463 A MYPI2010003463 A MY PI2010003463A MY PI2010003463 A MYPI2010003463 A MY PI2010003463A MY 178870 A MY178870 A MY 178870A
- Authority
- MY
- Malaysia
- Prior art keywords
- replicating
- mosquitoes
- attenuated recombinant
- incapable
- equine encephalitis
- Prior art date
Links
- 241000710929 Alphavirus Species 0.000 title abstract 4
- 241000255925 Diptera Species 0.000 title abstract 3
- 230000002238 attenuated effect Effects 0.000 title abstract 3
- 230000003362 replicative effect Effects 0.000 title abstract 2
- 241001502567 Chikungunya virus Species 0.000 abstract 1
- 241000710945 Eastern equine encephalitis virus Species 0.000 abstract 1
- 241000710959 Venezuelan equine encephalitis virus Species 0.000 abstract 1
- 241000710951 Western equine encephalitis virus Species 0.000 abstract 1
- 230000002163 immunogen Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000013598 vector Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C12N7/04—Inactivation or attenuation; Producing viral sub-units
- C12N7/045—Pseudoviral particles; Non infectious pseudovirions, e.g. genetically engineered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36161—Methods of inactivation or attenuation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36171—Demonstrated in vivo effect
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
- C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US6222908P | 2008-01-24 | 2008-01-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MY178870A true MY178870A (en) | 2020-10-21 |
Family
ID=41217313
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MYPI2010003463A MY178870A (en) | 2008-01-24 | 2009-01-23 | Attenuated recombinant alphaviruses incapable of replicating in mosquitoes and uses thereof |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US8426188B2 (enExample) |
| EP (2) | EP3085787B1 (enExample) |
| JP (1) | JP5758632B2 (enExample) |
| KR (2) | KR101668849B1 (enExample) |
| CN (1) | CN102083986B (enExample) |
| AU (1) | AU2009238667A1 (enExample) |
| CA (2) | CA2713165C (enExample) |
| CO (1) | CO6290702A2 (enExample) |
| IL (2) | IL207167A (enExample) |
| MX (3) | MX378503B (enExample) |
| MY (1) | MY178870A (enExample) |
| NZ (2) | NZ587502A (enExample) |
| SG (2) | SG10201606111XA (enExample) |
| WO (1) | WO2009131604A2 (enExample) |
| ZA (1) | ZA201005943B (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7850977B2 (en) * | 2007-06-21 | 2010-12-14 | Alphavax, Inc. | Promoterless cassettes for expression of alphavirus structural proteins |
| KR101668849B1 (ko) | 2008-01-24 | 2016-10-24 | 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 | 모기에서 복제 불가능한 약독화된 재조합 알파바이러스 및 그의 용도 |
| US8961995B2 (en) | 2012-09-20 | 2015-02-24 | Uab Research Foundation | Methods and compositions for alphavirus replicons |
| WO2014052588A1 (en) | 2012-09-27 | 2014-04-03 | Research Development Foundation | Attenuated chikungunya virus |
| CN111729077A (zh) | 2013-03-14 | 2020-10-02 | 武田疫苗股份有限公司 | 减毒活甲病毒制剂的组合物和方法 |
| CA3019536A1 (en) * | 2016-03-31 | 2017-10-05 | Takeda Vaccines, Inc. | Live, attenuated alphavirus constructs and methods and uses thereof |
| BR112018074277A2 (pt) * | 2016-05-27 | 2019-10-01 | Univ Griffith | vacina de alfavírus artrogênica |
| CA3062591A1 (en) | 2017-05-08 | 2018-11-15 | Gritstone Oncology, Inc. | Alphavirus neoantigen vectors |
| AU2019315577A1 (en) * | 2018-08-03 | 2021-03-25 | Uab Research Foundation | Methods and compositions for alphavirus vaccine |
| CN109536464B (zh) * | 2018-12-10 | 2022-06-10 | 中国科学院武汉病毒研究所 | 一种缺失衣壳蛋白基因的基孔肯雅病毒感染性克隆及构建方法和在制备减毒疫苗中的应用 |
| MX2021014525A (es) | 2019-05-30 | 2022-03-17 | Gritstone Bio Inc | Adenovirus modificados. |
| EP4085130A4 (en) | 2019-12-31 | 2024-04-10 | Elixirgen Therapeutics, Inc. | TEMPERATURE-BASED TRANSIENT DELIVERY OF NUCLEIC ACIDS AND PROTEINS TO CELLS AND TISSUES |
| CA3187258A1 (en) | 2020-08-06 | 2022-02-10 | Karin Jooss | Multiepitope vaccine cassettes |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6451592B1 (en) * | 1996-04-05 | 2002-09-17 | Chiron Corporation | Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis |
| CA2327189A1 (en) * | 2000-12-21 | 2002-06-21 | The Minister Of National Defence | Novel dna-based vaccine against the encephalitis alphaviruses |
| KR101518309B1 (ko) * | 2003-03-20 | 2015-05-08 | 알파벡스, 인크. | 개선된 알파바이러스 레플리콘 및 헬퍼 구축물 |
| AU2005256112B9 (en) | 2004-07-30 | 2008-09-25 | Blackberry Limited | Method and system for coordinating device setting between a communications client and its host device |
| US7332322B2 (en) | 2004-09-14 | 2008-02-19 | Ilya Frolov | Venezuelan equine encephalitis virus replicons with adaptive mutations in the genome and uses thereof |
| CA2579507C (en) | 2006-03-15 | 2017-06-13 | Institut Pasteur | Novel isolated and purified strains of chikungunya virus and polynucleotides and polypeptides sequences, diagnostic and immunogenical uses thereof |
| KR101668849B1 (ko) | 2008-01-24 | 2016-10-24 | 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 | 모기에서 복제 불가능한 약독화된 재조합 알파바이러스 및 그의 용도 |
-
2009
- 2009-01-23 KR KR1020107018777A patent/KR101668849B1/ko not_active Expired - Fee Related
- 2009-01-23 SG SG10201606111XA patent/SG10201606111XA/en unknown
- 2009-01-23 MX MX2019010530A patent/MX378503B/es unknown
- 2009-01-23 CA CA2713165A patent/CA2713165C/en not_active Expired - Fee Related
- 2009-01-23 MX MX2014010258A patent/MX367792B/es unknown
- 2009-01-23 KR KR1020167029024A patent/KR101913790B1/ko not_active Expired - Fee Related
- 2009-01-23 CN CN200980110510.1A patent/CN102083986B/zh not_active Expired - Fee Related
- 2009-01-23 MX MX2010007989A patent/MX2010007989A/es active IP Right Grant
- 2009-01-23 SG SG2013005624A patent/SG187513A1/en unknown
- 2009-01-23 NZ NZ587502A patent/NZ587502A/xx not_active IP Right Cessation
- 2009-01-23 WO PCT/US2009/000458 patent/WO2009131604A2/en not_active Ceased
- 2009-01-23 JP JP2010544350A patent/JP5758632B2/ja not_active Expired - Fee Related
- 2009-01-23 EP EP16000617.7A patent/EP3085787B1/en not_active Not-in-force
- 2009-01-23 MY MYPI2010003463A patent/MY178870A/en unknown
- 2009-01-23 EP EP09735287.6A patent/EP2250269B1/en not_active Not-in-force
- 2009-01-23 CA CA2910235A patent/CA2910235C/en not_active Expired - Fee Related
- 2009-01-23 NZ NZ603790A patent/NZ603790A/en not_active IP Right Cessation
- 2009-01-23 AU AU2009238667A patent/AU2009238667A1/en not_active Abandoned
-
2010
- 2010-07-22 IL IL207167A patent/IL207167A/en active IP Right Grant
- 2010-07-23 US US12/804,535 patent/US8426188B2/en active Active
- 2010-08-20 CO CO10102866A patent/CO6290702A2/es active IP Right Grant
- 2010-08-20 ZA ZA2010/05943A patent/ZA201005943B/en unknown
-
2013
- 2013-04-03 US US13/855,960 patent/US9580690B2/en active Active
-
2014
- 2014-04-09 IL IL232032A patent/IL232032A0/en unknown
-
2017
- 2017-02-27 US US15/443,364 patent/US10533186B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY178870A (en) | Attenuated recombinant alphaviruses incapable of replicating in mosquitoes and uses thereof | |
| Garousi | Duality constraints on effective actions | |
| HK1216618A1 (zh) | 新城疫病毒及其用途 | |
| MX2017004617A (es) | Variantes estabilizadas de alfa amilasa y su uso. | |
| PH12020500080A1 (en) | Senecavirus a immunogenic compositions and methods thereof | |
| ATE420965T1 (de) | Von tc-83 abgeleitete alphavirus-vektoren, partikel und verfahren | |
| NZ749279A (en) | Compositions and methods related to engineered fc constructs | |
| TN2012000567A1 (en) | Glucagon analogues | |
| PH12018502120A1 (en) | Live attenuated alphavirus constructs and methods and uses thereof | |
| PH12016502554A1 (en) | A dengue virus chimeric polyepitope composed of fragments of non structural proteins and its use in an immunogenic composition against dengue virus infection | |
| AU2016335217A8 (en) | Antigen receptors and uses thereof | |
| MX2017007868A (es) | Composiciones para proporcionar una proteccion de filtro solar mejorada. | |
| MX2019000172A (es) | Anticuerpos con inmunogenicidad baja y usos de estos. | |
| NZ631012A (en) | Compositions and methods for live, attenuated alphavirus formulations | |
| WO2009048633A3 (en) | Chimeric chikungunya virus and uses thereof | |
| MX2019002024A (es) | Antigenos de pertussis acelulares no entrelazados para uso en vacunas de combinacion. | |
| MY190399A (en) | A composition comprising cistanche and ginkgo extracts, the composition useful for improving memory of a subject | |
| MX2016000021A (es) | Sirna virus especifico del dengue, estructura arn oligo helicoidal, y composicion para la supresion de proliferacion del virus del dengue que comprende la estructura arn. | |
| EP2504029A4 (en) | COMPOSITIONS, METHODS AND USES FOR THE EXPRESSION OF PEPTIDES ASSOCIATED WITH ENTEROBACTERIA | |
| CA3156472A1 (en) | POLYMER COMPOSITION | |
| MX2018013556A (es) | Polipeptidos variantes con rendimiento mejorado y uso de los mismos. | |
| MX2019002497A (es) | Peptido con actividad para cicatrizacion de heridas. | |
| MX2019010572A (es) | Composicion que comprende avelumab. | |
| KR20180084482A (ko) | 권백 추출물을 유효성분으로 포함하는 상처 치유용 또는 피부 재생용 화장료 조성물 | |
| WO2014159592A3 (en) | Modified hyaluronan and uses thereof in cancer treatment |